# Evaluation of BAY59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients

> **NCT00044525** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 82 (actual)

## Conditions studied

- Breast Neoplasms
- Breast Cancer, Metastatic

## Interventions

- **DRUG:** BAY59-8862 (Cytotoxic Taxane)

## Key facts

- **NCT ID:** NCT00044525
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-04
- **Primary completion:** 2004-02
- **Final completion:** 2004-02
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2014-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00044525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00044525, "Evaluation of BAY59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00044525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*